

# Coping, Distress, and Survival Among Patients With Lung Cancer

Hermann Faller, MD, PhD; Heinrich Bülzebruck, PhD; Peter Drings, MD; Hermann Lang, MD, PhD

**Background:** This study addresses the question of whether coping and emotional state are predictors of survival among patients with lung cancer. The hypotheses were (1) active coping is linked with longer survival time and (2) depressive coping, emotional distress, and depression are linked with shorter survival.

**Methods:** The study was based on a sample of 103 patients who were investigated after their diagnosis and before the beginning of primary treatment. The psychological variables were assessed by means of self-reports and interviewer ratings. After follow-up of 7 to 8 years, 92 patients had died; survival data were censored for the remaining 11 patients. The prediction of the survival time was performed by the Cox regression, while adjusting for

biomedical risk factors (tumor stage, histological classification, and Karnofsky performance status).

**Results:** The self-reported depressive coping ( $P = .007$ ) and the interviewer-rated emotional distress ( $P = .04$ ) were significantly associated with shorter survival, independent of the influence of the biomedical prognostic factors.

**Conclusions:** Both coping and emotional distress had a statistically independent effect on survival among patients with lung cancer. However, the naturalistic design of the study does not allow for any causal interpretation. Thus, the nature of this relationship warrants further investigation.

*Arch Gen Psychiatry.* 1999;56:756-762

**T**HE QUESTION as to whether psychological factors influence survival among patients with cancer has stimulated considerable research. Previous research with breast cancer patients demonstrates that coping attitudes, such as a fighting spirit and denial, were predictive of longer survival, as compared with hopelessness and fatalism.<sup>1-4</sup> Many subsequent investigations, however, yielded conflicting findings and had methodological limitations.

The findings on the predictive power of active coping could partially be replicated in predictor<sup>5,6</sup> and intervention studies,<sup>7</sup> while the results regarding denial proved inconsistent.<sup>6,8-11</sup> However, other studies<sup>11-16</sup> produced evidence of a relationship between emotional distress and shorter survival. Yet even these results were inconclusive, because some researchers found that the expression of distress predicted a better outcome.<sup>7,17,18</sup> Moreover, other studies<sup>19-25</sup> did not detect any associations between psychological factors and survival. Consequently, the question of the impact of psychological variables on the course of cancer is still under discussion.<sup>26-34</sup>

There are few studies that address the relationship between the psychological factors and the course of the disease among patients with lung cancer. The prognosis of lung cancer is rather unfavorable. The 1-year survival rate is 37%, and the 5-year survival rate is 5% to 10%. Survival times may reflect tumor stage, performance status, and histological classification.<sup>35-45</sup> Patients with non-small cell tumors are usually treated surgically, but only 30% of these patients can be operated on with a curative intention. If resection is not possible, the tumor can be irradiated. Small cell tumors have an especially high rate of malignancy. The median survival time of a limited disease is 12 to 15 months and of an extensive disease, 6 to 9 months. Chemotherapy is the usual treatment, because small cell tumors tend to spread at an early stage. Radiation is given as an additional or palliative treatment.<sup>46,47</sup>

Because of the high rate of malignancy and rapid progression of lung cancer, it seems rather unlikely at first glance that psychological factors could play a significant role.<sup>48</sup> One study of patients with nonmetastatic non-small cell carcinomas did not detect any links between interviewer assessments of familial coping pat-

From the Institute of Psychotherapy and Medical Psychology, University of Würzburg, Würzburg, Germany (Drs Faller and Lang); and the Departments of Medical Informatics and Biostatistics (Dr Bülzebruck) and Oncology (Dr Drings), Thorax Clinic Heidelberg-Rohrbach, Heidelberg, Germany.

## SUBJECTS AND METHODS

### SAMPLE SELECTION

Only patients with lung cancer who were newly diagnosed and who had not yet begun their primary treatment were included in the sample. The sampling procedure aimed at a sample size of 50 patients with small cell carcinoma and 50 patients with non-small cell carcinoma. One hundred fifty-two newly diagnosed lung cancer patients, who had been admitted to a large tumor center (Thorax Clinic Heidelberg-Rohrbach, Heidelberg, Germany), and whose condition had been explained to them, were asked to participate in the study. Participants gave written informed consent. One hundred twenty patients agreed to participate. The relatively high refusal rate stems largely from implementation problems in the surgical wards, while the refusal rate in the internal wards was as low as 10%. The subsample that refused to participate contained more patients with non-small cell tumors who later received surgical treatment, and more women. It should be noted that the women, the surgically treated patients, and the patients with non-small cell tumors who did participate in the study did not differ significantly on the psychological variables when compared with the men, the nonsurgically treated patients, and the patients with small cell tumors. Another 17 patients had already been treated in other hospitals, which was only later revealed, and thus had to be excluded from the sample after being assessed psychologically. Consequently, the final sample consisted of 103 patients. The patients were recruited between June 1989 and December 1991. Follow-up assessments of survival times were performed in January 1998, which was 7 to 8 years after diagnosis. By this time, 92 patients had died.

### ASSESSMENT

Coping methods and affective states were assessed by both self-reports and interviewer ratings, as is recommended.<sup>6,15,31,53</sup> Assessments were completed within 3 days after confirmation of diagnosis. However, some patients had already received diagnostic tests prior to their admission to the study hospital and thus may have gained an idea about their disease. The interviewer ratings were performed on the

basis of the information obtained by a semistructured interview. The interview began with the request, "I would like you to tell me how it all began." Once the patients had described their history, the issue of emotional state was brought up with the questions, "Sometimes people feel depressed when they suffer from an illness like that. Do you know this sort of feeling yourself?" "Have you ever had feelings of anxiety during the course of your illness?" The basis for the interviewer ratings of coping was the question, "What helps you to come to terms with your situation?" The interviews were tape-recorded. The interviewers were advanced medical and psychology students who were familiar with the hospital ward setting, had received extensive training, and were supervised once a week. Details of the patients' medical records were unknown to the interviewers.

Coping was measured by the well-validated Freiburg Questionnaire of Coping With Illness,<sup>23,54</sup> which contains both a self-report format and an interviewer rating format. It consists of 35 short statements on coping behaviors (eg, "I am seeking information about illness and treatment") rated on a 5-point Likert scale with 1 indicating not at all and 5, very much. The interviewers rated the same 35 items. The *active, problem-focused coping* scale consisted of 5 items: seeking information about illness and treatment, undertaking problem-solving efforts, making plans of action and following them, intending to live more intensively, and deciding to fight against the illness (Cronbach  $\alpha$ : self-report, 0.64; interviewer rating, 0.74; and interrater reliability, Spearman  $\rho$ , 0.65). *Depressive coping* was measured by 5 items: brooding, arguing with fate, pitying oneself, acting impatiently and taking it out on others, and withdrawing from other people (Cronbach  $\alpha$ : self-report, 0.68; interviewer rating, 0.69; and interrater reliability, Spearman  $\rho$ , 0.78). The additive scales of the Freiburg Questionnaire of Coping With Illness were divided by the number of items, so that the scores ranged from 1 to 5.

To evaluate possible interviewer biases, we computed an analysis of variance for the different interviewers. One interviewer rated the active coping scale systematically higher ( $P < .001$ ). However, this interviewer bias did

Continued on next page

terns and survival.<sup>13</sup> In 2 studies<sup>49,50</sup> with positive findings, severe methodological limitations were evident: well-established prognostic factors were not taken into account, psychological variables were assessed after the completion of treatment, and multiple variables were tested retrospectively. However, Kaasa et al<sup>51</sup> demonstrated that patients with inoperable non-small cell lung cancer had a longer survival if their psychological well-being was good. In a recent study<sup>52</sup> of newly diagnosed lung cancer patients, self-reported depression predicted shorter survival after controlling for biomedical prognostic factors such as stage of the disease and performance status. However, in this study, post hoc-selected single items of a standardized test (rather than the total scores of the entire test) were used as predictors in the multivariate model. Moreover, it remains unclear how the authors chose their multivariate model, which did not contain patients' physical performance. Neither the study by Kaasa et al<sup>51</sup> nor Buccheri<sup>52</sup> assessed coping styles. To summarize, evidence on the prognostic significance of both coping and affective state among

patients with lung cancer is rather weak. Above all, there are only a few prospective studies that have been aimed at addressing this important and unresolved question.

We conducted a prospective study, with a 7- to 8-year follow-up, to determine whether both coping and emotional distress were predictors of survival among patients with lung cancer, while controlling for biomedical prognostic factors. Assessments were performed before patients began treatment. The hypotheses that guided the study were that active coping is linked with longer survival, and that depressive coping, emotional distress, and depression are linked with shorter survival.

## RESULTS

### DEMOGRAPHIC AND BIOMEDICAL DATA

The mean (SD) age of the participants was 59 (9) years (range, 32-84 years). Eight-three percent were men. Age

not seem to influence the results, because there were no significant differences of survival time among the patients judged by the different interviewers, and the effects were even reproduced when the 7 patients who were rated by the biased interviewer were excluded.

*Emotional distress* was measured by a newly developed scale consisting of the following 5 items: I am anxious, I am depressed, I am distressed by the disease, I am distressed by the diagnostic tests, and I am nervous. Respondents were asked to rate themselves on 5-point scales ranging from 1 (not at all) to 5 (very much). The sum scores of the scale were divided by the number of items, so that the scores had values between 1 and 5. The outside estimates given by the interviewers were performed using analogous statements (eg, the patient is anxious, etc). Cronbach  $\alpha$  values were 0.82 (self-report) and 0.87 (interviewer rating). Interrater reliability (Spearman  $\rho$ ) was 0.70. Validation data of this clinical scale have been presented elsewhere.<sup>55,56</sup>

The degree of *depression* was measured by means of the well-established Depression Scale D-S.<sup>57,58</sup> It was designed to assess the intensity of depressive, anxious, and irritable or dysphoric mood rather than the nosological entity of depression (sample items: I feel depressed and melancholic. Often I feel miserable. Recently I have been very anxious and nervous.). It can be used to evaluate both healthy persons and psychiatric patients. Each of the 16 items is rated on a 4-point scale from 0 to 3, yielding a total possible depression score ranging from 0 to 48.

Unfortunately, there is no validated German version of any internationally accepted instrument for the assessment of coping. As for depression, German versions of both the Beck Depression Inventory and the Hospital Anxiety and Depression Scale have become available in the meantime. However, these instruments were published in 1993 and 1995, respectively, after the assessments in our study had been completed.

The following *biomedical variables*, which were routinely collected by the study hospital, were taken into account: histological cell type, tumor stage, and Karnofsky performance status.<sup>59</sup> The Karnofsky performance status is a clinician's appraisal of the level of patient's functioning.

In addition, the attending physicians made 3 ratings concerning (1) severity of the disease, (2) unfavorable prognosis, and (3) expected treatment success. These judgments were performed before the commencement of treatment. They were rated on 5-point scales, with 1 indicating not at all and 5, very much.

## STATISTICAL PROCEDURES

The outcome variable was time from diagnosis to death. Survival times are often censored data. Here the term "censored" means that the total survival time is only known for patients who have already died. For patients who are still alive, the only available information is on the length of survival from the time of diagnosis to the last point of observation. In the present sample, 92 patients were deceased and 11 were censored. With these kind of data, the probabilities of survival can be computed with the method of Kaplan and Meier.<sup>60</sup> The statistical comparison of the probabilities was performed using the log-rank test. For the Kaplan-Meier analysis, the continuous variables were dichotomized at the median. We first tested the individual effects of the psychological and biomedical variables on survival. Then the Cox proportional hazards regression model<sup>61-63</sup> was used to determine the relationship between psychological variables and survival adjusted for multiple covariates. Biomedical and psychological variables that proved significant in the bivariate tests were simultaneously entered into the Cox regression. To examine whether the association between independent variables and survival is influenced by the levels of interrelated variables, we included the terms describing the interaction of independent variables. Furthermore, we ensured that the included variables satisfied the assumptions of the Cox model by modeling them as binary variables (median split). Stage was split in the following manner: stages I, II, IIIa vs IIIb, and IV. The testing for proportional hazards functions was done with empiric log(-log)-plots and with the acceleration test of Breslow.<sup>62</sup>  $P < .05$  was considered significant, and all  $P$  values reflect 2-tailed tests. The statistical analyses were performed using SPSS 8.0 for Windows (SPSS Inc, Chicago, Ill).

and sex composition corresponded with the data given in the literature.<sup>46,47</sup> Seventy-nine percent were married. For 84% of the patients, the highest level of education was middle school. The respondents were employed as unskilled workers (23%), skilled workers (22%), and middle-level salaried employees (40%). Of these, 33% had already retired by the time of investigation.

Histological classifications were as follows: small cell ( $n = 48$ ), squamous cell ( $n = 30$ ), adenocarcinoma ( $n = 17$ ), large cell ( $n = 4$ ), mixed ( $n = 4$ ). One patient was stage I, 8 were stage II, 21 were stage IIIa, 30 were stage IIIb, and 43 were stage IV. As expected from the sampling criteria, patients with small cell carcinoma and those with advanced-stage disease were overrepresented. This fact is reflected in the frequencies of treatments: the majority of patients received chemotherapy ( $n = 15$ ), radiotherapy ( $n = 14$ ), or both ( $n = 44$ ). Thirty patients were treated surgically. Of the surgical patients, 14 received additional radiation, 2 received chemotherapy, and 2 received both. Histological classification, tumor stage, and type of treatment were

interrelated. Only 1 patient with small cell tumor was given surgical treatment. Patients with non-small cell lung cancer were more frequently operated on when their tumors were in earlier stages. The respective figures were: stage I/II, 100%; stage IIIa, 73%; stage IIIb, 56%; and stage IV, 17%. The mean (SD) score on the Karnofsky performance scale was 82 (13) (median, 80).

## INTERCORRELATIONS OF PSYCHOLOGICAL AND BIOMEDICAL VARIABLES

**Table 1** shows that self-reports and interviewer ratings of a specific construct were correlated. Different indicators of depressive mood (depressive coping, emotional distress, and depression) were interrelated, whereas active coping was independent of these. There were no effects of age and tumor stage on psychological variables. The Karnofsky performance status was correlated with active coping, as judged by the interviewers, and, inversely, depression. Physician ratings were on the whole

**Table 1. Means and Correlations of Psychological and Biomedical Variables (n = 103)\***

	No.	Mean	SD	Intercorrelations of Psychological Variables							Correlations With Biomedical Variables					
				2	3	4	5	6	7	Age	Stage	KPS	Physician Ratings†			
													1	2	3	
Active coping, IR	103	2.81	0.74	0.38‡	-0.04	0.05	-0.12	0.14	-0.07	0.05	-0.08	0.32‡	-0.01	-0.06	0.16	
Active coping, SR	97	3.48	0.96		0.08	-0.10	-0.04	0.13	-0.03	-0.00	0.13	0.17	-0.01	-0.01	0.08	
Depressive coping, IR	103	2.30	0.63			0.41‡	0.57‡	0.46‡	0.45‡	-0.05	0.04	0.08	0.07	0.17	-0.03	
Depressive coping, SR	97	1.69	0.67				0.31‡	0.32‡	0.39‡	-0.02	0.04	-0.13	0.02	0.13	-0.24‡	
Emotional distress, IR	103	2.95	0.90					0.58‡	0.36‡	-0.04	0.04	0.14	-0.00	0.13	-0.01	
Emotional distress, SR	98	2.33	0.93						0.55‡	-0.02	0.05	0.10	0.04	0.23‡	-0.20	
Depression, D-S	92	5.52	5.18							-0.04	0.11	-0.24‡	0.10	0.14	-0.16	

\*KPS indicates Karnofsky performance status; IR, interviewer rating; SR, self-report; and D-S, Depression Scale.

†Physician rating 1, severity; physician rating 2, unfavorable prognosis; and physician rating 3, expected treatment success.

‡Spearman correlation coefficients; significant at  $P < .05$ .

**Table 2. Kaplan-Meier Analyses of Survival With Psychological Predictors (n = 103)\***

Variable	Cutoff Points (Median Split)	No.	Median Survival, mo	P
Active coping, IR (n = 103)	≤2.6	53	7	.17
	>2.6	50	15	
Active coping, SR (n = 97)	≤3.6	49	11	.99
	>3.6	48	12	
Depressive coping, IR (n = 103)	≤2.2	56	12	.13
	>2.2	47	12	
Depressive coping, SR (n = 97)	≤1.6	58	14	.007
	>1.6	39	9	
Emotional distress, IR (n = 103)	≤3.0	56	15	.02
	>3.0	47	9	
Emotional distress, SR (n = 98)	≤2.2	50	14	.31
	>2.2	48	10	
Depression, SR (n = 92)	≤4	51	12	.19
	>4	41	10	

\*IR indicates interviewer rating; SR, self-report. Comparison of survival distributions by log-rank test.

fairly unrelated to psychological variables, yet highly interrelated: the severity rating was correlated with the unfavorable prognosis rating ( $r = 0.57, P < .001$ ) and the treatment success rating ( $r = -0.47, P < .001$ ), and these 2 ratings were also interrelated ( $r = -0.68, P < .001$ ). No differences in psychological variables were noted between histological cell types.

#### KAPLAN-MEIER ANALYSES OF SURVIVAL PROBABILITIES

**Table 2** shows the results of the Kaplan-Meier analysis of survival probabilities for the psychological scales that were dichotomized at the median. Median splits did not always result in equal frequencies within the subgroups, because the scale values representing the medians were occupied by more than 1 patient. Two of the 7 median split tests were significant. Patients with high values of self-reported depressive coping had significantly shorter survival than patients with low values. Emotionally distressed patients had shorter times of survival, when assessed by the interviewer ratings.

**Table 3. Cox Proportional Hazards Regression on Survival (n = 93)**

Variable	Regression Coefficient	SE	P
Tumor stage	-0.89	0.26	<.001
Karnofsky performance status	0.94	0.24	<.001
Depressive coping, self-report	-0.90	0.33	.007
Emotional distress, interviewer rating	-0.76	0.37	.04
Interaction of depressive coping, self-report, and emotional distress, interviewer rating	0.46	0.48	.34

The biomedical predictors that were related with survival time were tumor stage ( $P = .002$ ), Karnofsky performance status ( $P < .001$ ), and histological cell type, ie, small cell vs non-small cell tumors ( $P = .01$ ). In addition, physicians' ratings of the severity of the disease were predictive of shorter survival ( $P = .02$ ), and a tendency was also revealed in their judgments of an unfavorable prognosis ( $P = .07$ ). However, their estimates of expected treatment success ( $P = .54$ ), age ( $P = .72$ ), and sex ( $P = .91$ ) were not significant predictors.

#### COX REGRESSION USING MULTIPLE COVARIATES

Psychological and biomedical variables that showed a significant effect on survival in the bivariate analyses were entered into the Cox proportional hazards regression model. Thus, included among the psychological variables were both the self-report of depressive coping and the interviewer rating of emotional distress. The effect of an interaction between these 2 variables was also examined. Of the biomedical variables, tumor stage and Karnofsky performance status were taken into account. **Table 3** shows that the tumor stage, the Karnofsky performance status, the self-report of depressive coping, and the interviewer rating of emotional distress were independent predictors of survival.

When cell type and its interaction with tumor stage were included in the multivariate model, the self-report of depressive coping ( $P = .006$ ), the interviewer rating of



emotional distress ( $P = .02$ ), and the Karnofsky performance status ( $P < .001$ ) remained significant. However, both tumor stage and cell type were no longer significant as single variables, but their interaction proved to have an effect on survival ( $P = .01$ ).

The physician rating of the severity of the disease was not entered into the Cox regression during the first step because to do so would have unduly restricted the model's statistical power (sample size,  $n = 78$ ). However, when the physician rating was included in the model, it showed no independent effect on survival ( $P = .44$ ). Yet the predictive effects of the tumor stage ( $P = .02$ ), the Karnofsky performance status ( $P = .001$ ), the self-report of depressive coping ( $P = .04$ ), and the interviewer rating of emotional distress ( $P = .04$ ) remained significant.

To test the suggestion that patients who showed depressive coping or were emotionally distressed might prematurely discontinue chemotherapy, we correlated the number of chemotherapy cycles that part of the patients later received with the coping measures, and found a significant negative correlation with the self-report of depressive coping ( $r = -0.27$ ,  $P = .04$ ), but not with the interviewer rating of emotional distress ( $r = -0.14$ ,  $P = .30$ ). However, when the number of cycles was included in the Cox model ( $n = 57$ ), the interviewer rating of emotional distress remained significant ( $P = .04$ ), while the number of cycles proved nonsignificant ( $P = .63$ ). In this subgroup analysis, the self-report of depressive coping only revealed a trend ( $P = .12$ ), as did both the tumor stage ( $P = .12$ ) and the Karnofsky performance status ( $P = .06$ ), probably reflecting reduced statistical power that comes from the smaller sample size.

#### COMMENT

In this study, both self-reported depressive coping and interviewer-rated emotional distress were independently associated with shorter survival among patients with lung cancer. Adjusting for biomedical risk factors, these effects remained significant.

There are several strengths to the study. The study was prospective and guided by hypotheses. It started before the commencement of treatment and thereby guaranteed that the psychological measures that were assessed at that time were not influenced by prior treatment. However, the possibility cannot be excluded that psychological variables were indicators of the course of the disease prior to the time of assessment. Since many patients had late-stage cancers, they possibly had some time to develop coping strategies and emotional distress before the assessments were performed. In addition, the physicians' opinions could have been conveyed to them and might have influenced their emotional state. Furthermore, we cannot rule out the possibility that the links we found were produced by some unknown intervening variables.<sup>48</sup> A major limitation in our study stems from the relatively small size and the selectivity of the sample, in which advanced stages and small cell tumors were over-represented. Moreover, the study only reports cross-sectional data regarding psychological variables.

Our findings concur with those of other studies that suggest that both emotional distress and depressive cop-

ing predict shorter survival.<sup>11-16,51</sup> The link determined between the interviewer ratings and survival may reflect a crucial issue: the raters may have based their judgments on their perceptions of the physical state of the patient. However, the self-reports of depressive coping were predictive as well. The degree of distress may be influenced by such coping attitudes as denial or stoicism. The prognostic significance of both the tumor stage and the Karnofsky performance status was confirmed in our sample.<sup>35-45</sup>

Several models for the relationship between coping and the course of cancer can be conceptualized.<sup>31,64,65</sup> The course of the disease may have some impact on coping, either in a direct manner via psychologically active paraneoplastic hormones,<sup>66,67</sup> or in a more indirect manner through the emotional reaction of the patients to bodily symptoms. The physical damage is sometimes reflected better by psychological variables, which are closer to the patients' experience than the cruder biomedical staging classifications. Thus, several studies have shown quality of life to be an independent predictor of survival in patients with lung<sup>49,51,68-72</sup> and other cancers.<sup>73-76</sup>

Coping may influence the course of the disease, either in a direct manner via psychoneuroimmunological mechanisms (eg, active coping might increase and depressive coping decrease natural killer cell activity),<sup>7,77-82</sup> or in an indirect manner via compliance,<sup>83</sup> such as when patients who cope actively might receive a higher amount of chemotherapy whereas those who are depressed might discontinue such therapy earlier.<sup>84</sup>

To conclude, the present study revealed some evidence pointing to a relationship between coping, distress, and survival among patients with lung cancer, after controlling for biomedical risk factors.

Accepted for publication May 3, 1999.

This work was supported by the Cancer Patient Rehabilitation Programme of the German Government run by the Ministry for Research and Technology (grant 0706879).

We thank the members of the project group: Andreas Fütterer; Regina Gösswein, MD; Maria Maier, MD; Martina Otteni, Dipl-Psych; Stefan Schilling, Dipl-Psych; Guntram Söhngen, MD; Klaus Stetter; and Jürgen Wagner, Dipl-Psych.

Reprints: Hermann Faller, MD, PhD, Institute of Psychotherapy and Medical Psychology, University of Würzburg, Klinikstrasse 3, D 97070 Würzburg, Germany.

#### REFERENCES

1. Greer S, Morris T. Psychological attributes of women who develop breast cancer: a controlled study. *J Psychosom Res.* 1975;19:147-153.
2. Greer S, Morris T, Pettingale KW. Psychological response to breast cancer: effect on outcome. *Lancet.* 1979;2:785-787.
3. Pettingale KW, Morris T, Greer S, Haybittle JL. Mental attitudes to cancer: an additional prognostic factor [letter]. *Lancet.* 1985;1:750.
4. Greer S, Morris T, Pettingale KW, Haybittle JL. Psychological response to breast cancer and 15 year outcome. *Lancet.* 1990;1:49-50.
5. Hislop GT, Waxler NE, Coldman AJ, Elwood JM, Kan L. The prognostic significance of psychosocial factors in women with breast cancer. *J Chronic Dis.* 1987;40:729-735.
6. Morris T, Pettingale K, Haybittle J. Psychological response to cancer diagnosis and disease outcome in patients with breast cancer and lymphoma. *Psychooncology.* 1992;1:105-114.

7. Fawzy FI, Fawzy NW, Hyun CS, Elashoff R, Guthrie D, Fahey JL, Morton DL. Malignant melanoma: effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival 6 years later. *Arch Gen Psychiatry*. 1993;50:681-689.
8. Rogentine GN, Van Kammen DP, Fox BH, Docherty JP, Rosenblatt JE, Boyd SC, Bunney Jr WE. Psychological factors in the prognosis of malignant melanoma: a prospective study. *Psychosom Med*. 1979;41:647-655.
9. Dean C, Surtees PG. Do psychological factors predict survival in breast cancer? *J Psychosom Res*. 1989;33:561-569.
10. Epping-Jordan JE, Compas BE, Howell DC. Predictors of cancer progression in young adult men and women: avoidance, intrusive thoughts, and psychological symptoms. *Health Psychol*. 1994;13:539-547.
11. Ratcliffe MA, Dawson AA, Walker LG. Eysenck Personality Inventory L-scores in patients with Hodgkin's disease and non-Hodgkin's lymphoma. *Psychooncology*. 1995;4:39-45.
12. DiClemente RJ, Temoshok L. Psychological adjustment to having cutaneous malignant melanoma as a predictor of follow-up clinical status [abstract]. *Psychosom Med*. 1985;47:81.
13. Wirsching M, Drings P, Georg W, Hoffmann F, Riehl J, Schlag P, Schmidt P. Psychosoziale Faktoren der Gesunderhaltung? *Psychother Med Psychol*. 1990;40:70-75.
14. Levy SM, Herberman RB, Lippman M, D'Angelo T, Lee J. Immunological and psychosocial predictors of disease recurrence in patients with early-stage breast cancer. *Behav Med*. 1991;17:67-75.
15. Tschuschke V, Pfeleiderer K, Denzinger R, Hertenstein B, Kächele H, Arnold R. Coping bei Knochenmarkstransplantation: Ein Beitrag zur Frage des "geeigneten vs. ungeeigneten Copings." *Psychother Psychosom Med Psychol*. 1994;44:346-354.
16. Gilbar O. The connection between the psychological condition of breast cancer patients and survival: a follow-up after eight years. *Gen Hosp Psychiatry*. 1996;18:266-270.
17. Derogatis LR, Abeloff MD, Melisaratos N. Psychological coping mechanisms and survival time in metastatic breast cancer. *JAMA*. 1979;242:1504-1508.
18. Temoshok L, Fox BH. Coping styles and other psychosocial factors related to medical status and to prognosis in patients with cutaneous malignant melanoma. In: Fox BH, Newberry BH, eds. *Impact of Psychoendocrine Systems in Cancer and Immunity*. New York, NY: CJ Hogrefe; 1984:258-287.
19. Cassileth BR, Lusk EJ, Miller DS, Brown LL, Miller C. Psychosocial correlates of survival in advanced malignant disease. *N Engl J Med*. 1985;312:1551-1555.
20. Holland JC, Korzun AH, Tross S, Cella DF, Norton L, Wood W. Psychosocial factors and disease-free survival in stage II breast cancer [abstract]. *Proc Am Soc Clin Oncol*. 1986;5:237.
21. Jamison RN, Burish TG, Wallston KA. Psychogenic factors in predicting survival of breast cancer patients. *J Clin Oncol*. 1987;5:768-772.
22. Richardson JL, Zarnegar Z, Bisno B, Levine A. Psychosocial status at initiation of cancer treatment and survival. *J Psychosom Res*. 1990;34:189-201.
23. Buddeberg C, Sieber M, Wolf C, Landolt-Ritter C, Richter D, Steiner R. Are coping strategies related to disease outcome in early breast cancer? *J Psychosom Res*. 1996;40:255-264.
24. Tross S, Herdon J II, Korzun A, Kornblith AB, Cella DF, Holland JF, Raich P, Johnson A, Kiang DT, Perloff M, Norton L, Wood W, Holland JC, for the Cancer and Leukemia Group. Psychological symptoms and disease-free and overall survival in women with stage II breast cancer. *J Natl Cancer Inst*. 1996;88:661-667.
25. Giraldi T, Rodani MG, Cartei G, Grassi L. Psychosocial factors and breast cancer: a 6-year Italian follow-up study. *Psychother Psychosom*. 1997;66:229-236.
26. Spiegel D, Bloom JR, Kraemer HC, Gotthel E. Effect of psychosocial treatment on survival of patients with metastatic breast cancer. *Lancet*. 1989;2:888-891.
27. Cooper CL, Watson M, eds. *Cancer and Stress*. Chichester, England: Wiley & Sons; 1991.
28. Levenson JL, Bemis C. The role of psychological factors in cancer onset and progression. *Psychosomatics*. 1991;32:124-132.
29. Mulder CL, van de Pompe G, Spiegel D, Antoni MH, deVries MJ. Do psychosocial factors influence the course of breast cancer? a review of recent literature, methodological problems and future directions. *Psychooncology*. 1992;1:155-167.
30. Fox BH. Some problems and some solutions in research on psychotherapeutic intervention in cancer. *Support Care Cancer*. 1995;3:257-263.
31. Hürny C. Psychische und soziale Faktoren in Entstehung und Verlauf maligner Erkrankungen. In: Uexküll TV, ed. *Psychosomatische Medizin*. 5th ed. Munich, Germany: Urban u. Schwarzenberg; 1995:953-969.
32. Cunningham AJ, Edmonds CVI, Jenkins GP, Pollack H, Lockwood GA, Warr D. A randomized controlled trial of the effects of group psychological therapy on survival in women with metastatic breast cancer. *Psychooncology*. 1998;7:508-517.
33. Fox B. A hypothesis about Spiegel et al's 1989 paper on psychosocial intervention and breast cancer survival. *Psychooncology*. 1998;7:361-370.
34. Holland JC, ed. *Psycho-Oncology*. New York, NY: Oxford University Press Inc; 1998.
35. O'Connell JP, Kris MG, Gralla RJ, Groshen S, Trust A, Fiore JJ, Kelsen DP, Heelan RT, Golbey RE. Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. *J Clin Oncol*. 1986;4:1604-1614.
36. Sakurai M, Shinkai T, Eguchi K, Sasaki Y, Tamura T, Miura K, Fujiwara Y, Otsu A, Horuchi N, Nakano H, Nahagava K, Hong WS, Saijo N. Prognostic factors in non-small cell lung cancer: multiregression analysis in the National Cancer Center Hospital (Japan). *J Cancer Res Clin Oncol*. 1987;113:563-566.
37. Sorensen JB, Badsberg JH, Olsen J. Prognostic factors in inoperable adenocarcinoma of the lung: a multivariate regression analysis of 259 patients. *Cancer Res*. 1989;49:5748-5754.
38. Bernhard J. Therapiestudien mit "Lebensqualitäts"-Variablen beim Bronchuskarzinom: Eine methodenkritische Übersicht. In: Schwarz R, Bernhard J, Flechtner H, Kuchler T, Hürny C, eds. *Lebensqualität in der Onkologie*. Munich, Germany: Zuckschwerdt; 1991:74-88.
39. Bülzebruck H, Drings P, Kayser K, Schulz V, Tuengerthal S, Vogt-Moykopf I. Classification of lung cancer: first experiences with the new TNM classification (4th edition). *Eur Respir J*. 1991;4:1197-1206.
40. Holle R, Flechtner H. Ergebnisse der Lebensqualitätserhebungen der BMFT-Studien zur Therapie des kleinzelligen Bronchialkarzinoms. In: Schwarz R, Bernhard J, Flechtner H, Kuchler T, Hürny C, eds. *Lebensqualität in der Onkologie*. Munich, Germany: Zuckschwerdt; 1991:89-100.
41. Shinkai T, Eguchi K, Sasaki Y, Tamura T, Ohe Y, Kojima A, Oshita F, Miya T, Okamoto H, Iemura K. A prognostic-factor risk index in advanced non-small-cell lung cancer treated with cisplatin-containing combination chemotherapy. *Cancer Chemother Pharmacol*. 1992;30:1-6.
42. Buccheri G, Ferrigno D. Prognostic factors in lung cancer: tables and comments. *Eur Respir J*. 1994;7:1350-1364.
43. Feld R, Sagman U, LeBlanc M. Staging and prognostic factors: small cell lung cancer. In: Pass HI, Mitchell JB, Johnson DH, Turrisi AT, eds. *Lung Cancer: Principles and Practice*. Philadelphia, Pa: Lippincott-Raven; 1996:495-509.
44. Moore DF, Lee JS. Staging and prognostic factors: non-small cell lung cancer. In: Pass HI, Mitchell JB, Johnson DH, Turrisi AT, eds. *Lung Cancer: Principles and Practice*. Philadelphia, Pa: Lippincott-Raven; 1996:481-494.
45. Ohlhauser C, Bülzebruck H, Ebert W, Drings P, Wannenmacher M. Prognostic factors for survival in inoperable non-small-cell lung cancer: a multivariate regression analysis of 456 patients with radiation therapy. *Onkologie*. 1994;20:126-131.
46. Drings P, Vogt-Moykopf I. Das nicht kleinzellige Bronchialkarzinom. *Dtsch Ärzteblatt*. 1988;85:1469-1473.
47. Drings P, Vogt-Moykopf I. Das kleinzellige Bronchialkarzinom. *Dtsch Ärzteblatt*. 1988;85:1369-1372.
48. Levy SM, Roberts DC. Clinical significance of psychoneuroimmunology: prediction of cancer outcomes. In: Schneiderman N, McCabe P, Baum A, eds. *Stress and Disease Processes*. Hillsdale, NJ: Lawrence A Erlbaum Associates; 1992:165-174.
49. Kukull WA, McCorkle R, Driever M. Symptom distress, psychosocial variables, and survival from lung cancer. *Psychosoc Oncol*. 1986;4:91-104.
50. Stavratsy KM, Donner AP, Kincade JE, Stewart MA. The effect of psychosocial factors on lung cancer mortality at one year. *J Clin Epidemiol*. 1988;41:75-82.
51. Kaasa S, Mastekaasa A, Lund E. Prognostic factors for patients with inoperable non-small cell lung cancer, limited disease. *Radiother Oncol*. 1989;15:235-242.
52. Buccheri G. Depressive reactions to lung cancer are common and often followed by a poor outcome. *Eur Respir J*. 1998;11:173-178.
53. Lazarus RS. Coping theory and research: past, present, and future. *Psychosom Med*. 1993;55:234-247.
54. Muthny FA. *Freiburger Fragebogen zur Krankheitsverarbeitung*. Weinheim, Germany: Beltz; 1989.
55. Faller H, Schilling S, Lang H. Verbessert Coping das emotionale Befinden? Ergebnisse einer Längsschnittuntersuchung mit Bronchialkarzinompatienten. *Psychother Psychosom Med Psychol*. 1994;44:355-364.
56. Faller H, Lang H, Schilling H. Emotional distress and hope in lung cancer patients, as perceived by patients, relatives, physicians, nurses and interviewers. *Psychooncology*. 1995;4:21-31.
57. von Zerßen D, Strian F, Schwarz D. Evaluation of depressive states, especially in longitudinal studies. In: Pichot P, Olivier-Martin R, eds. *Psychological Measurement in Psychopharmacology. Modern Problems in Pharmacopsychiatry*. Vol 7. Basel, Switzerland: S Karger AG; 1974:189-202.
58. Zerßen DV. *Paranoid-Depressivitäts-Skala und Depressivitäts-Skala*. Weinheim, Germany: Beltz; 1976.
59. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM, ed. *Evaluation of Chemotherapeutic Agents*. New York, NY: Columbia University Press; 1949:191-205.
60. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. *J Am Stat Assoc*. 1958;53:457-481.

61. Cox DR. Regression models and life tables. *J R Stat Soc.* 1972;B34:187-220.
62. Breslow NE, Edler L, Berger J. A two-sample censored-data rank test for acceleration. *Biometrics.* 1984;40:1049-1062.
63. Edler L. Auswertungsstrategien mit dem Cox'schen Regressionsmodell zur Bestimmung prognostischer Faktoren. In: Überla K, Reichertz PL, Victor N, eds. *Medizinische Informatik und Statistik.* Berlin, Germany: Springer; 1986:403-406.
64. Holland JC. Behavioral and psychosocial risk factors in cancer: human studies. In: Holland JC, Rowland JH, eds. *Handbook of Psychooncology.* Oxford, England: Oxford University Press; 1989:705-726.
65. Andersen BL, Kiecolt-Glaser JK, Glaser R. A biobehavioral model of cancer stress and disease course. *Am Psychol.* 1994;49:389-404.
66. Holland JC. Lung cancer. In: Holland JC, Rowland JH, eds. *Handbook of Psychooncology.* Oxford, England: Oxford University Press; 1989:180-187.
67. Bernhard J, Ganz PA. Psychosocial issues in lung cancer patients (part 1 and 2). *Chest.* 1991;99:216-223, 480-485.
68. Ganz PA, Lee JJ, Siau J. Quality of life assessment: an independent prognostic variable for survival in lung cancer. *Cancer.* 1991;67:3131-3135.
69. Ruckdeschel S, Piantadosi S, and the Lung Cancer Study Group. Quality-of-life assessment in lung surgery for bronchogenic carcinoma. *Theor Surg.* 1991;6:201-205.
70. Buccheri GF, Ferrigno D, Tamburini M, Brunelli C. The patient's perception of his own quality of life might have an adjunctive prognostic significance in lung cancer. *Lung Cancer.* 1995;12:45-58.
71. Degner LF, Sloan JA. Symptom distress in newly diagnosed ambulatory cancer patients and as a predictor of survival in lung cancer. *J Pain Symptom Manage.* 1995;10:423-431.
72. Montazeri A, Gillis CR, McEwen J. Quality of life in patients with lung cancer: a review of literature from 1970 to 1995. *Chest.* 1998;113:467-481.
73. Coates A, GebSKI V, Signorini D, Murray P, McNeil D, Byrne M, Forbes JF, for the Australian New Zealand Breast Cancer Trials Group. Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. *J Clin Oncol.* 1992;10:1833-1838.
74. Andrykowski MA, Brady MJ, Henslee-Downey PJ. Psychosocial factors predictive of survival after allogeneic bone marrow transplantation for leukemia. *Psychosom Med.* 1994;56:432-439.
75. Molassiotis A, van den Akker BA, Milligan DW, Goldman JM. Symptom distress, coping style and biological variables as predictors of survival after bone marrow transplantation. *J Psychosom Res.* 1997;42:275-285.
76. Dancey J, Zee B, Osoba D, Whitehead M, Lu F, Kaizer L, Latreille J, Pater JL. Quality of life scores: an independent prognostic variable in a general population of cancer patients receiving chemotherapy. *Qual Life Res.* 1997;6:151-158.
77. Levy S, Herberman R, Lippman M, d'Angelo T. Correlation of stress factors with sustained depression of natural killer cell activity and predicted prognosis in patients with breast cancer. *J Clin Oncol.* 1987;5:348-353.
78. Fawzy FI, Kemeny ME, Fawzy NW, Elashoff R, Morton D, Cousins N, Fahey JL. A structured psychiatric intervention for cancer patients. II: changes over time in immunological measures. *Arch Gen Psychiatry.* 1990;47:729-735.
79. Stein M, Miller AH, Trestman RL. Depression, the immune system, and health and illness: findings in search of meaning. *Arch Gen Psychiatry.* 1991;48:171-177.
80. McDaniel JS, Musselman DL, Porter MR, Reed DA, Nemeroff CB. Depression in patients with cancer: diagnosis, biology, and treatment. *Arch Gen Psychiatry.* 1995;52:89-99.
81. Walker LG, Millar LL, Peterson KA, Friend JAR, Gough D, Whiting PW, Eremin O. Do psychological factors predict immunosuppression in patients with lung cancer and benign lung disease [abstract]? *Psychooncology.* 1996;5(suppl):69.
82. Andersen BL, Farrar WB, Golden-Kreutz D, Kutz LA, MacCallum R, Courtney ME, Glaser R. Stress and immune response after surgical treatment for regional breast cancer. *J Natl Cancer Inst.* 1998;90:30-36.
83. Richardson JL, Shelton DR, Krailo M, Levine AM. The effect of compliance with treatment on survival among patients with hematologic malignancies. *J Clin Oncol.* 1990;8:356-364.
84. Gilbar O, Kaplan-De Nour A. Adjustment to illness and drop-out of chemotherapy. *J Psychosom Res.* 1989;33:1-5.